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Neurounina-1 [chemical name: 7-nitro-5-phenyl-1-(pyrrolidin-1-ylmethyl)-1H-
benzo[e][1,4]diazepin-2(3H)-one] is a new compound provided with relevant
neuroprotective effect during stroke and in neonatal hypoxia by increasing the
Na+/Ca2+ exchanger (NCX) isoforms NCX1 and NCX2 activity. This study shows for
the first time, the development and validation of a sensitive and selective method for
analysis of neurounina-1 in beagle dog plasma by liquid chromatography coupled
to tandem mass spectrometry (LC-MS/MS). The sample preparation consisted of
extraction of the analyte and the internal standard (IS) (ropivacaine) from plasma
(50 µL) by liquid-liquid extraction using acetonitrile (100 µL). The selected reaction
monitoring mode of the positive ion was performed and the precursor to the product ion
transitions of m/z 365 > 83 and m/z 275 > 126 were used to measure the derivative of
neurounina-1 and ropivacaine. The chromatographic separation was achieved using a
Phenomenex C18 Luna (150 mm × 4.6 mm × 5 µm) analytical column with an isocratic
mobile phase composed of methanol/acetonitrile/water (50/40/10, v/v/v) + 0.1%
formic acid + 1 M ammonium formate. The method was linear over a concentration
range of 1–500 ng/mL. The method was applied to evaluate the pharmacokinetics
of neurounina-1 after a single intravenous administration of three different doses
(0.1 mg/kg, 0.3 mg/kg, and 1 mg/kg) to beagle dogs (n = 5). The mean AUC0−tlast
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values were 26.10, 115.81, and 257.28 ng∗h/mL following intravenous administration
of 0.1, 0.3, and 1 mg/kg, respectively. Linear pharmacokinetics was observed up to
1.0 mg/kg. The neurounina-1 was rapidly eliminated, with mean CL values of 46.24,
47.57, and 69.15 L/h, Vd of 130.31, 154.15, and 210.79 L and t1/2 of 2.14, 2.54,
and 2.04 h after intravenous administration of 0.1, 0.3, and 1 mg/kg, respectively.
This new analytical method allows the rapid determination of the neurounina-1, a new
developed compound, able to exert a remarkable neuroprotective effect in the low
nanomolar range.
Keywords: neurounina-1, Na+/Ca2+ exchanger (NCX), LC-MS/MS, beagle dog plasma, pharmacokinetics
INTRODUCTION
Stroke is a leading cause of long-lasting injury, disability, and
death. Early treatment and preventive measures can reduce the
brain damage that occurs as a result of a stroke. Several studies
have demonstrated that the activation of the three Na+/Ca2+
exchanger (NCX) isoforms, NCX1, NCX2, and NCX3 exerts
a neuroprotective action against stroke injury in adult mice
(Pignataro et al., 2004a,b; Jeon et al., 2008; Molinaro et al., 2008,
2016) and against neonatal hypoxic-ischemic encephalopathy
damage (Cerullo et al., 2018). Therefore, in recent years, the
interest has been focused on the identification of NCX activator
aiming to have new therapeutic tools able to limit the extension
of ischemic brain damage (Annunziato et al., 2004). With this
purpose, the structure of one of the most potent inhibitors, SM-
15811, was modified obtaining 7-nitro-5-phenyl-1-(pyrrolidin-
1-ylmethyl)-1H-benzo[e][1,4]diazepin-2(3H)-one, a new small
molecule named neurounina-1 that was patented in 2012
(Pignataro et al., 2012). Several pharmacological experiments
have demonstrated that this compound exerts a remarkable
neuroprotective effect during stroke by stimulation of NCX1
and NCX2 activities (Molinaro et al., 2013). Neurounina-1 has a
wide therapeutic window, as shown in an in vivo mouse model
of transient middle cerebral artery occlusion (tMCAO). When
intraperitoneally administered at doses of 0.003 to 30 µg/kg to
mouse, neurounina-1 effect was notable even 5 h after ischemia
induction, unlike other drugs used to date for treating stroke,
which require a much earlier administration. Furthermore,
neurounina-1 presents a high lipophilicity index and low toxicity
(Molinaro et al., 2013).
To support pre-clinical studies with neurounina-1, the
development of a bioanalytical method to monitor its
concentration in biological matrices is required. There is
no available method for neurounina-1 quantification. Moreover,
its half maximal effective concentration (EC50) is in the
picomolar to low nanomolar range (Molinaro et al., 2013), which
requires a low dose administration and consequently, a sensitive
and selective method of quantification.
This study presents for the first time, the development
and validation of a sensitive and selective method to quantify
neurounina-1 in beagle dog plasma using liquid chromatography
coupled to tandem mass spectrometry (LC-MS/MS), with
ropivacaine as internal standard (IS). The method showed a
lower limit of quantification (LLOQ) of 1.0 ng/mL, which
was used to evaluate the pharmacokinetics in plasma after
a single intravenous administration of three different doses
of neurounina-1 (0.1 mg/kg, 0.3 mg/kg, and 1 mg/kg) to
beagle dogs (n = 5).
MATERIALS AND METHODS
Chemical and Reagents
Ropivacaine was utilized as IS and was supplied by the
United States Pharmacopeia (Rockville, MD, United States).
Neurounina-1 was synthesized in house according to the
previously reported study (Molinaro et al., 2013). Acetonitrile
and methanol (HPLC grade) were purchased from J.T Baker
(Phillipsburg, NJ, United States); ammonium acetate and hexane
(analysis grade) from J.T Baker (Ecatepec, Mexico); ethyl
ether (analysis grade) from Mallinckrodt (Phillipsburg, NJ,
United States). The water was obtained from the purification
system Synergy UV R© (Millipore, Molsheim, France).
Calibration Standards and Quality
Control
Stock solutions of neurounina-1 and ropivacaine were prepared
in methanol/water (50/50, v/v). Calibration curves for
neurounina-1 were prepared by adding the compound to
blank plasma to yield final concentrations of 1, 2, 10, 50, 100, 200,
350, and 500 ng/mL. The calibration curves were performed in
duplicate for each day’s assays. The quality control (QC) samples
were prepared in blank plasma at the concentrations of 1, 1.5,
30, 240, and 400 ng/mL, respectively. For each validation, seven
replicates were analyzed for each CQ level (three validations
were performed). The spiked plasma samples (standards and
QC) were extracted in each analytical batch along with the
unknown samples.
Sample Preparation
Aliquots (0.05 mL) of each plasma sample were added to glass
tubes followed by 0.05 mL of IS (ropivacaine 100 ng/mL). The
tubes were vortexed for 5 s and 0.1 mL of acetonitrile were added.
The samples were vortexed for 40 s, again, and then centrifuged at
2000 × g for 5 min. The obtained supernatants were transferred
to microvials for analysis.
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Instrumentation and Software
Liquid Chromatography
Neuronina-1 was separated in a 150 mm × 4.6 mm x 5 µm
Phenomenex C18Luna reversed phase analytical column
(Phenomenex Inc., CA, United States). The temperature of the
column was maintained constant at 65◦C. The mobile phase
used was composed by methanol/acetonitrile/water (50/40/10,
v/v/v)+ 0.1% of formic acid+ 1 M ammonium formate at a flow
rate of 1 mL/min (split 1:3). The auto-sampler was maintained at
room temperature.
Mass Spectrometry
The mass spectrometer (Quattro Micro – Micromass, Waters,
United Kingdom) equipped with an electrospray source in
the ESI positive polarity mode (ES+) was configured for
multiple reaction monitoring (MRM) to monitor the transitions
365.3 > 83.9 and 275.2 > 126.0, for neurounina-1 and
ropivacaine, respectively. Figure 1 shows the full scan spectra
(upper trace) and the product ion spectra (lower trace) obtained
by the proposed fragmentation pathways for neurounina-1 (panel
A) and ropivacaine (panel B). To optimize all MS parameters, a
standard solution of the analyte and IS was infused into the mass
spectrometer. The optimized values of ion spray voltage, collision
energy, and cone voltage were, respectively 2800 (V), 20 (eV),
and 20 (V) for neurounina-1 and 2800 (V), 15 (eV), and 15 (V)
for ropivacaine. Data acquisition and analysis were performed
using the software Masslynx 4.0 (Waters Corporation, Milford,
MA, United States).
Method Validation
The method validation was carried out according to the
United States Food and Drug Administration (FDA, 2001)
bioanalytical method validation guidance and the Brazilian
National Sanitary Surveillance Agency (Agência Nacional de
Vigilância Sanitária [ANVISA], 2003).
Linearity
Calibration curves were prepared by assaying standard plasma
samples at eight concentrations of neurounina-1 (1, 2, 10, 50, 100,
200, 350, and 500 ng/mL) and the linearity of each calibration
curve was determined by plotting the peak area ratio (y) of
neurounina-1/ropivacaine vs. nominal concentration of analyte.
The calibration curve was constructed by weighted (1/X) least
squares linear regression.
Accuracy and Precision
The precision and accuracy of assay was determined at five
different concentrations (1.0, 1.5, 30, 240, and 400 ng/mL),
selected based on the literature and comparison with the
previously established analytical values for similar studies. The
following criteria were found to approve precision and intra-race
accuracy: (i) for each concentration level, coefficient of variation
(CV) that does not exceed 15% for LLOQ and 20% for QC
samples; (ii) mean value of the samples at each concentration
level, within 85 – 115% of the actual value for LLOQ and 80–
120% for QC samples.
Recovery and Matrix Effect
The recovery was evaluated by dividing the extracted sample
mean response by the unextracted (spiked blank plasma extract)
sample mean of the corresponding concentration. The matrix
effect experiments were carried out using the ratio between
spiked mobile phase solutions and unextracted samples, spiked
on plasma residues.
Stability
To assess stability, QC plasma samples (1.5 and 400.0 ng/mL)
were subjected to short-term (6 h) incubation at room
temperature; four freeze/thaw (−20◦C) cycles and 52 h
in the autosampler at room temperature. Subsequently, the
neurounina-1 concentrations were measured and compared with
freshly prepared samples.
Animals, Drug Administration and Blood
Sampling
Beagle dogs (n = 5) of both sexes, aged between 2 and 3 years old,
weighing between 10 and 14 kg were provided by Camilo Castelo
Branco University, Brazil. The dogs were housed in Domingos
Alves Veterinary Hospital in individual rooms and fed with a
standard canine food. They had free access to water. The dogs
underwent rigorous veterinary control and were all considered
healthy based on physical examination and laboratory analysis
performed before initiation and after completion of each occasion
of the study. At the end of the study, the animals were returned
to their habitat. This study was carried out in accordance with
the recommendations of the general ethical guidelines established
by the Brazilian Society for Laboratory Animal Science (SBCAL).
The protocol was approved by the Committee for Ethics in
Animal Use – State University of Campinas (CEUA/UNICAMP,
protocol n◦ 3340-1).
After an overnight (8 h) fasting, a single intravenous dose
of 0.1 mg/kg, 0.3 mg/kg, or 1 mg/kg neurounina-1 formulation
was administered to beagle dogs, with 7 days washout period
between each dose administration. Blood samples (5 mL) from
a suitable antecubital vein were collected into heparin-containing
tubes before and 0.03, 0.08, 0.17, 0.25, 0.33, 0.5, 1, 2, 3, 4, 6, 8, 12,
and 24 h after the administration of each dose. A total of 210 mL
of blood was collected during the study. The blood samples
treated with sodium heparin were centrifuged at approximately
2000 × g for 10 min at 4◦C and the plasma was stored at
−20◦C until analysis.
Pharmacokinetic and Statistical Analysis
Non-compartmental analysis was used to determine the
pharmacokinetic parameters of neurounina-1 after the
intravenous administration. The concentration at time zero
(C0) was estimated by back-extrapolating from the elimination
curve. The area under the plasma concentration vs. time curves
from zero to the last detectable concentration (AUC0−tlast) were
calculated by applying the linear-log trapezoid rule. Extrapolation
of these areas to infinity (AUC0−inf) was done by adding the
value Clast/ke to the calculated AUC0−tlast (where Clast = the
last detectable concentration). Clearance (CL) was calculated
by the formula dose/AUC0−inf. Volume of distribution (Vd)
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FIGURE 1 | Full scan mass spectrum of the protonated molecular ion of neurounina-1 – m/z = 365.3 (A), ion product of neurounina-1 – m/z = 83.9 (B), protonated
molecular ion of ropivacaine – m/z = 275.16 (C), and the ion product of ropivacaine – m/z = 126.09 (D).
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was calculated by the formula CL/ke. The WinNonlin software,
version 6.4 (Pharsight Corp, Mountain View, CA, United States)
was used. Statistical analysis was performed using GraphPad




Direct infusion was used to determine the best mass spectrometry
conditions for neurounina-1 and ropivacaine. The spectrum
FIGURE 2 | Chromatograms obtained in the analysis of neurounina-1 in beagle dog plasma. (A) Blank beagle dog plasma; (B) Blank beagle dog plasma spiked with
neurounina-1 (lower limit of quantification (LLOQ – 1.0 ng/mL) and ropivacaine (internal standard – IS, 100 ng/mL).
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for neurounina-1 showed a protonated molecular ion at
m/z 365.3 and its collision-induced dissociation formed a
distinctive product at m/z 83.9, corresponding to the 1-
methylenepyrrolidinium ion. Ropivacaine showed a base peak
ion ([M + H]+) at mass-to-charge ratio (m/z) of 275.16 and a
fragmentation product at m/z 126.09, corresponding to the 1-
propyl-2,3,4,5-tetrahydropyridinium ion (Figure 1). The selected
reaction monitoring is based on the m/z 365.3 > 83.9 and
275.2 > 126.0 transitions, for neurounina-1 and ropivacaine,
respectively. The total run time was 3.8 min (Figure 2).
Ropivacaine was selected as the IS because of its behavior and
structural similarity with neurounina-1.
The method was linear regression for neurounina-1
concentrations from 1 to 500 ng/mL (calibration curve
y = 0.00767312x + 0.00170099, r = 0.997172). A linear
regression with a weighting index of 1/x was performed
on the peak area ratios of neurounina-1 and the IS vs.
neurounina-1 concentrations of the eight beagle dogs
plasma standards (in duplicate) to generate a calibration
curve. The LLOQ, defined as the lowest concentration at
which both the precision and accuracy were <20%, was
1.0 ng/mL. No endogenous peak was observed in the mass
chromatogram of blank plasma (Figure 2). The retention
times for neurounina-1 and IS were 2.27 min and 2.26 min,
respectively (Figure 2).
Reproducibility of the Method
The within- and between-run precision and accuracy for
the LLOQ and QCs, summarized in Table 1, insure the
reproducibility and repeatability of the results.
The recovery obtained with the method of extraction of
neurounina-1 with acetonitrile was higher than 89%. The matrix
effect was practically absent in the analysis of neurounina-1
in beagle dog plasma (Table 2). Values >91% were obtained
when the peak areas resulting from the injection of standard
solutions in the mobile phase were compared with those of
standard solutions added to extracts of blank plasma from
eight different lots.
TABLE 1 | Accuracy and precision data for neurounina-1 from the pre-study validation in beagle dog plasma.
Nominal value 1 ng/mL 1.5 ng/mL 30 ng/mL 240 ng/mL 400 ng/mL
Batch identification Val. 1 Val. 2 Val. 3 Val. 1 Val. 2 Val. 3 Val. 1 Val. 2 Val. 3 Val. 1 Val. 2 Val. 3 Val. 1 Val. 2 Val. 3
Individual concentration values 1.3 1.05 1.26 1.75 1.66 1.74 30.75 29.02 29.03 225.83 230.3 224.19 390.3 401.4 384.91
1.13 1.01 0.88 1.52 1.72 1.46 30.78 29.01 28.68 228.15 237.39 227.31 393.52 400.99 383.35
1.15 0.86 1.17 1.41 1.64 1.66 30.41 29.08 30.16 224.93 230.01 231.55 399.52 386.85 376.37
1.21 1.04 0.81 1.52 1.28 1.55 29.84 30.96 29.35 228.29 229.99 225.94 386.95 392.3 382.44
1.19 1.1 1.08 1.32 1.68 1.59 29.13 31.31 29.74 229 232.18 230.03 404.31 404.53 377.86
1.22 1.11 1.09 1.71 1.8 1.6 28.71 28.45 29.71 234.66 232.4 226.96 392.94 389.26 374.23
0.98 1.05 0.88 1.65 1.48 1.68 28.81 29.49 27.89 226.92 226.12 228.19 387.97 397.01 375.87
Mean (ng/mL) 1.17 1.03 1.02 1.55 1.61 1.61 29.8 29.6 29.2 228 231 228 394 396 379
Intra-run precision (CV%) 8.5 8.1 16.5 10.2 10.8 5.7 3.0 3.7 2.6 1.4 1.5 1.1 1.6 1.7 1.1
Intra-run accuracy (%) 116.9 103.1 102.4 103.6 107.2 107.4 99.3 98.7 97.4 95.1 96.3 94.9 98.4 99.0 94.8
Inter-run mean (ng/mL) 1.075 1.59 29.54 229.1 389.7
Inter-run precision (CV%) 12.6 8.9 3.1 1.4 2.4
Inter-run accuracy (%) 107.5 106.1 98.5 95.4 97.4
Val, validation; CV% = [(SD/M) × 100]; Accuracy % = [(E − T)/T] × 100; CV, coefficient of variation; M, mean; SD, standard deviation of M; E, experimentally determined
concentration; T, theoretical concentration.
TABLE 2 | Recovery and matrix effect for neurounina-1 in eight different lots of beagle dog plasma (4 normal, 2 lipemic, and 2 hemolysate).













Individual peak area values 123.5 133.8 125.0 32951 31780.1 29320.2
107.3 131.9 106.9 32867.8 32355.4 31935.9
145.2 126.5 120.7 33273.9 34053.7 29296.7
Mean 125.3 130.7 117.5 33031 32730 30184
CV(%) 15.2 2.9 8.0 0.6 3.6 5.0
Recovery(%) 89.9 92.2
Matrix effect(%) 93.8 91.4
CV %, coefficient of variation = [(SD/M) × 100]; M, mean; SD, standard deviation of M.
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Stability of Neurounina-1
The stability tests indicated that no significant degradation of
neurounina-1 occurred during four freezing and thawing cycles,
over a period of 6 h at room temperature and after processing in
the self-injector for 52 h at 5◦C, as shown in Table 3.
Pharmacokinetic Parameters of
Neurounina-1
The mean neurounina-1 plasma concentration vs. time profiles
after a single intravenous dose administration of 0.1, 0.3, and
1 mg/kg neurounina-1 to beagle dogs (n = 5) are shown
in Figure 3. The obtained neurounina-1 pharmacokinetic
parameters are presented in Table 4. The mean AUC0−tlast
values were 26.10, 115.81, and 257.28 ng∗h/mL following
intravenous administration of 0.1, 0.3, and 1 mg/kg, respectively.
Linear pharmacokinetics was observed up to 1.0 mg/kg. The
neurounina-1 was rapidly eliminated, with mean CL values of
46.24, 47.57, and 69.15 L/h, Vd of 130.31, 154.15, and 210.79 L
and t1/2 of 2.14, 2.54 and 2.04 h after intravenous administration
of 0.1, 0.3 and 1 mg/kg, respectively.
DISCUSSION
The present study shows, for the first time, a selective and
sensitive method for analysis of neurounina-1 in beagle dog
plasma using LC-MS/MS. One of the most advantages is that this
method does not require deuterated analogs.
The LC-MS/MS method presented a good sensitivity (LLOQ
of 1 ng/mL) and permits a high throughput. Furthermore,
this method is simple and selective for quantification and
pharmacokinetic evaluation of neurounina-1 in beagle dog
plasma. Indeed, this method was applied to evaluate the
pharmacokinetics of neurounina-1 after a single intravenous
administration of three different doses (0.1 mg/kg, 0.3 mg/kg, and
TABLE 3 | Stability tests for neurounina-1 in beagle dog plasma.
Estability Freeze/thaw (4cycles) Short-term (6 h) Post-processing (52 h)
Concentration (1.5 ng/mL) (400 ng/mL) (1.5 ng/mL) (400 ng/mL) (1.5 ng/mL) (400 ng/mL)
Individual value 1.44 401.76 1.37 419.00 1.39 398.17
1.39 403.30 1.34 426.97 1.62 407.43
1.35 410.78 1.55 432.58 1.32 416.33
Mean 1.39 405 1.42 426 1.44 407
CV(%) 3.2 1.2 8.0 1.6 10.9 2.2
Accuracy(%) 92.7 101.3 94.7 106.5 96.0 101.8
CV% = [(SD/M) × 100]; Accuracy % = [(E − T)/T] × 100; CV, coefficient of variation; M, mean; SD, standard deviation of M; E, experimentally determined concentration;
T, theoretical concentration.
FIGURE 3 | Neurounina-1 plasma concentration vs. time profile obtained after a single intravenous administration of 0.1, 0.3, and 1 mg/kg of neurounina-1 to beagle
dogs (n = 5). Data are expressed as mean and standard deviation.
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TABLE 4 | Pharmacokinetic parameters after a single intravenous administration
of 0.1, 0.3, and 1 mg/kg of neurounina-1 to beagle dogs (n = 5).
Parameter Mean SD Min Median Max CV%
Neurounina-1 (0.1 mg/kg)
AUC0−inf (ng∗h/mL) 30.10 9.92 23.05 26.44 44.47 32.95
AUC0−tlast (ng∗h/mL) 26.10 9.85 18.37 23.00 40.01 37.74
AUC%extrap (%) 4.00 0.82 2.84 3.42 4.68 20.54
C0 (ng/mL) 32.47 7.24 24.90 30.64 41.50 22.30
CL (L/h) 46.24 11.30 31.93 47.69 59.17 24.44
Ke (h−1) 0.35 0.07 0.29 0.38 0.43 20.39
t1/2 (h) 2.02 0.40 1.60 1.67 2.38 20.10
Vd (L) 130.31 17.94 109.65 126.86 151.55 13.76
Neurounina-1 (0.3 mg/kg)
AUC0−inf (ng∗h/mL) 122.42 64.73 35.68 133.20 213.80 52.88
AUC0−tlast (ng∗h/mL) 115.81 65.88 28.53 127.76 208.96 56.88
AUC%extrap (%) 6.61 2.14 4.28 4.56 9.63 32.33
C0 (ng/mL) 110.54 90.32 44.80 100.43 260.00 81.71
CL (L/h) 47.57 41.36 19.92 35.47 120.24 86.95
Ke (h−1) 0.30 0.05 0.22 0.31 0.35 16.45
t1/2 (h) 2.36 0.44 1.95 2.16 3.10 18.91
Vd (L) 154.15 112.84 61.82 102.96 338.35 73.20
Neurounina-1 (1 mg/kg)
AUC0−inf (ng∗h/mL) 263.06 192.08 150.98 184.06 601.44 73.02
AUC0−tlast (ng∗h/mL) 257.28 190.91 147.67 179.65 593.62 74.20
AUC%extrap (%) 5.78 1.92 3.31 4.55 7.82 33.16
C0 (ng/mL) 222.90 170.33 34.70 196.62 490.00 76.42
CL (L/h) 69.15 31.93 17.12 74.91 94.05 46.17
Ke (h−1) 0.33 0.04 0.30 0.32 0.40 11.90
t1/2 (h) 2.13 0.23 1.75 1.94 2.30 10.66
Vd (L) 210.79 96.51 51.89 224.15 307.70 45.79
AUC, area under the plasma concentration vs. time curve; t1/2, elimination half-life;
Ke, elimination rate constant; CL, clearance; Vd, volume of distribution.
1 mg/kg) to beagle dogs. Linear pharmacokinetics was observed
up to 1.0 mg/kg. Nevertheless, the high lipophilicity index of
neurounina-1, it showed a low half-life with mean CL values of
46.24, 47.57, and 69.15 L/h, Vd of 130.31, 154.15, and 210.79 L
and t1/2 of 2.14, 2.54, and 2.04 h after intravenous administration
of 0.1, 0.3, and 1 mg/kg, respectively.
Remarkably, prediction analysis revealed that neurounina-1
possesses a high lipophilicity and, thus, a high capability of
crossing the blood-brain barrier (BBB), with an estimated log
P of 0.87 (n-octanol/water). This aspect is further highlighted
by data on the Vd. Indeed, the high Vd values of neurounina-1
confirm the ability of this compound to reach the CNS and
support its indication in neurological disorders. As concern,
the possible breakdown of BBB after stroke may alter its
permeability (Krueger et al., 2017). Therefore, experiments
carried out in healthy animals could show lower levels
of the drug in the brain tissue. On the other hands, the
pharmacokinetic profile determined in beagle dogs correlates
with the in vitro and in vivo therapeutic effect observed in
neurons exposed to oxygen glucose deprivation (OGD) and in
adult mice subjected to transient occlusion of middle cerebral
artery and in neonatal hypoxic mice treated intraperitoneally
with neurounina-1 (30 µg/kg) (Cerullo et al., 2018). The
dosage used in the present study is in a higher range of
that exerting a protective effect in mice cortical neurons
exposed to OGD. Furthermore, the most effective dosage of
neurounina-1 in an animal model of stroke was 0.03 µg/Kg,
administered 3 h after stroke induction (Molinaro et al.,
2013), much smaller than the dosage range administered to
beagle dogs. A protection, less marked than that obtained with
0.03 µg/Kg neurounina-1, was also seen when neurounina-1
was used at a dose of 0.003 µg/Kg (Molinaro et al., 2013).
Notably, the administration of neurounina-1 seemed to
be well tolerated by the animals and no sign of behavior
modification were observed.
A possible major limitation of this study is the relative short
half-life of neurounina-1, around 2 h. For its potential use
during the acute stroke episode, intravenous infusion of the drug
could be eventually done. However, for the sub-acute or chronic
administration of the compound, its fast elimination rate could
be an important drawback.
CONCLUSION
The developed and validated method to quantify neurounina-1
in beagle dog plasma using LC-MS/MS presented sensitivity and
selectivity, thus allowing the rapid and precise determination of
the pharmacokinetics of this neuroprotective compound working
in the low nanomolar range.
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